Cantor Fitzgerald Reiterates Their Buy Rating on Jazz Pharmaceuticals (JAZZ)

In a report released today, Brandon Folkes from Cantor Fitzgerald reiterated a Buy rating on Jazz Pharmaceuticals (JAZZ), with a price target of $185. The company’s shares opened today at $127.76.

Folkes said:

“: Post 4Q18, we reiterate our Overweight rating and 12-mo. PT of $185 JAZZ shares. Jazz continues to grow its core sleep franchise and has been able to successfully build a pipeline in sleep and hemo/oncology to follow its Xyrem success. We believe that the sleep franchise durability remains underappreciated, driven by JZP-258, and that the company has an interesting hemo/oncology business that could drive the next leg of growth and evolution for JAZZ. We believe that data readouts in 2019 and upwards earnings revisions in both segments of the business will drive upside to JAZZ’s current share price.”

According to TipRanks.com, Folkes is a 3-star analyst with an average return of 3.5% and a 41.8% success rate. Folkes covers the Healthcare sector, focusing on stocks such as Opiant Pharmaceuticals Inc, Eagle Pharmaceuticals Inc, and Collegium Pharmaceutical.

Jazz Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $177.33, a 38.8% upside from current levels. In a report issued on February 12, Oppenheimer also maintained a Buy rating on the stock with a $175 price target.

See today’s analyst top recommended stocks >>

Jazz Pharmaceuticals’ market cap is currently $7.62B and has a P/E ratio of 15.11. The company has a Price to Book ratio of 2.55.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry.